SCHEMBL3097457

SCHEMBL3097457

CN(C)C(=O)Nc1snc(OCc2cccc(Cl)c2Cl)c1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
POLB P06746 1/20 0.36
CARM1 Q86X55 1/20 0.36
PTPRC P08575 1/20 0.35
PTPRG P23470 1/20 0.35
PKM P14618 1/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
NR4A2 P43354 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
P2RX7 Q99572 2/20 0.34
CCR4 P51679 1/20 0.34
ALDH1A1 P00352 2/20 0.33
IDO1 P14902 1/20 0.33
TP53 P04637 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4850017 0.91 ACVR2A (0.40) KMT2AMEN1POLBCARM1PKM
SCHEMBL3086781 0.82 ACVR2A (0.41) KMT2AMEN1POLBPKMCASP3
SCHEMBL7832129 0.82 PPARG (0.42) KMT2AMEN1CASP3SENP8SENP7
SCHEMBL7830755 0.81 TSHR (0.41) KMT2AMEN1POLBSENP8SENP7
SCHEMBL7832645 0.79 ACVR2A (0.34) KMT2AMEN1POLBRAB9AP2RX7
SCHEMBL7834007 0.78 NR4A2 (0.44) NR4A2
SCHEMBL7819943 0.76 KMT2A (0.44) KMT2AMEN1POLBPKMNPC1
SCHEMBL7832071 0.76 POLB (0.44) KMT2AMEN1POLBNPC1RAB9A
SCHEMBL7830660 0.76 PDGFRB (0.38) KMT2AMEN1POLBP2RX7ALDH1A1
SCHEMBL7820761 0.75 LTA4H (0.41) KMT2AMEN1POLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790902-B2 Isothiazole derivatives useful as anticancer agents PFIZER, INC. (US) 2010-09-07 US disclosed
US-20080300249-A1 tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents PFIZER, INC. (US) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300249-A1 tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents CDKN1A, TK1, CDK1 KMT2A 1265/4885MEN1 1782/4885POLB 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.